Pediatric Nephrology

, Volume 26, Issue 3, pp 411–417 | Cite as

Cyclosporin A therapy for Henoch–Schönlein nephritis with nephrotic-range proteinuria

  • Jee Min Park
  • Sung Chul Won
  • Jae Il Shin
  • Hyunee Yim
  • Ki Soo PaiEmail author
Original Article


To evaluate the therapeutic role of cyclosporin A (CyA) for the treatment of Henoch–Schönlein nephritis (HSN), 29 patients (18 boys, 11 girls) with nephrotic-range proteinuria were analyzed retrospectively. Mean age was 8.6 years (range 2.0–15.5 years) at diagnosis of Henoch–Schönlein purpura (HSP). All patients had developed the nephrotic-range proteinuria at a mean interval of 4.4 months (range 0–50.7 months) after the diagnosis of HSP. Mean duration of CyA treatment was 12.3 months (range 2.6–55.0 months). Mean follow-up times were 3.7 years (range 1.2–12.9 years) from the beginning of the CyA treatment. Steroids were tapered off and stopped gradually after initiation of CyA. All patients responded to the CyA treatment within a mean of 1.8 months (range 1 week to 3.5 months). Twenty-three patients achieved stable remission with mean follow-up duration of 3.2 years and 6 patients seemed to become CyA-dependent, since they developed proteinuria when the treatment was stopped. Renal function was preserved in all patients but one who developed end-stage renal disease after poor compliance with CyA. We concluded that CyA treatment for HSN showing nephrotic-range proteinuria is very effective and a safe method, although some patients become CyA-dependent.


Henoch–Schönlein nephritis Cyclosporin A Nephrotic-range proteinuria 


  1. 1.
    Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, Kawasaki T, Lindsley C, Petty RE, Prieur AM, Ravelli A, Woo P (2006) EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 65:936–941CrossRefGoogle Scholar
  2. 2.
    Kaku Y, Nohara K, Honda S (1998) Renal involvement in Henoch-Schönlein purpura: a multivariate analysis of prognostic factors. Kidney Int 53:1755–1759PubMedCrossRefGoogle Scholar
  3. 3.
    Ronkainen J, Nuutinen M, Koskimies O (2002) The adult kidney 24 years after childhood Henoch-Schönlein purpura. A retrospective cohort study. Lancet 360:666–670PubMedCrossRefGoogle Scholar
  4. 4.
    Goldstein AR, White RHR, Akuse R, Chantler C (1992) Long-term follow-up of childhood Henoch-Schönlein nephritis. Lancet 339:280–282PubMedCrossRefGoogle Scholar
  5. 5.
    Ronkainen J, Ala-Houhala M, Huttunen N-P, Jahnukainen T, Koskimies O, Örmälä T, Nuutinen M (2003) Outcome of Henoch-Schönlein nephritis with nephrotic-range proteinuria. Clin Nephrol 60:80–84PubMedGoogle Scholar
  6. 6.
    Ronkainen J, Autio-Harmainen H, Nuutinen M (2003) Cyclosporin A for the treatment of severe Henoch-Schönlein glomerulonephritis. Pediatr Nephrol 18:1138–1142PubMedCrossRefGoogle Scholar
  7. 7.
    Shin JI, Park JM, Shin YH, Kim JH, Kim PK, Lee JS, Jeong HJ (2005) Cyclosporin A therapy for severe Henoch-Schönlein nephritis with nephrotic syndrome. Pediatr Nephrol 20:1093–1097PubMedCrossRefGoogle Scholar
  8. 8.
    Someya T, Kaneko K, Fujinaga S, Ohtaki R, Hira M, Yamashiro Y (2004) Cyclosporine A for heavy proteinuria in a child with Henoch-Schönlein purpura nephritis. Pediatr Int 46:111–113PubMedCrossRefGoogle Scholar
  9. 9.
    Counahan R, Winterborn MH, White RHR, Heaton JM, Meadow SR, Bluett NH, Swetschin H, Cameron JS, Chantler C (1977) Prognosis of Henoch-Schönlein nephritis in children. Br Med J 2:11–14PubMedCrossRefGoogle Scholar
  10. 10.
    Koskimies O, Mir S, Rapola J, Vilska J (1981) Henoch-Schonlein nephritis: long-term prognosis of unselected patients. Arch Dis Child 56:482–484PubMedCrossRefGoogle Scholar
  11. 11.
    Goldstein AR, White RH, Akuse R, Chantler C (1992) Long term follow-up of childhood Henoch-Schonlein nephritis. Lancet 339:280–282PubMedCrossRefGoogle Scholar
  12. 12.
    Tarshish P, Bernstein J, Edelmann CM Jr (2004) Henoch-Schönlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatr Nephrol 19:51–56PubMedCrossRefGoogle Scholar
  13. 13.
    Maschio G, Alberti D, Janin G, Locatelli F, Mann J, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939–945PubMedCrossRefGoogle Scholar
  14. 14.
    Hausberg M, Barenbrock M, Hohage H, Müller S, Heidenreich S, Rahn K-H (1999) ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 33:862–868PubMedGoogle Scholar
  15. 15.
    Anarat A, Noyan A, Gonlusen G, Duman N, Tuncer D (1996) Influence of enalapril on experimental cyclosporin A nephrotoxicity. Pediatr Nephrol 10:616–620PubMedCrossRefGoogle Scholar
  16. 16.
    Inoue Y, Iijima K, Nakamura H, Yoshikawa N (1999) Two year cyclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 13:33–38PubMedCrossRefGoogle Scholar
  17. 17.
    Seikaly MG, Prashner H, Nolde-Hurlbert B, Browne R (2002) Long-term clinical and pathological effect of cyclosporin in children with nephrosis. Pediatr Nephrol 14:214–217CrossRefGoogle Scholar
  18. 18.
    Iijima K, Hamahira K, Tanaka R, Kobayashi A, Nozu K, Nakamura H, Yoshikawa N (2002) Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int 61:1801–1805PubMedCrossRefGoogle Scholar
  19. 19.
    Kano K, Kyo K, Yamada Y, Ito S, Ando T, Arisaka O (1999) Comparison between pre- and posttreatment clinical and renal biopsies in children receiving low doses ciclosporine-A for 2 years for steroid-dependent nephrotic syndrome. Clin Nephrol 52:19–24PubMedGoogle Scholar
  20. 20.
    Habib R, Niaudet P (1994) Comparison between pre- and posttreatment renal biopsies in children receiving ciclosporine for idiopathic nephrosis. Clin Nephrol 42:1446–1456Google Scholar
  21. 21.
    Tanaka H, Suzuki K, Nakahata T, Ito E, Waga S (2003) Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis. Pediatr Nephrol 18:347–350PubMedGoogle Scholar
  22. 22.
    Shin JI, Park JM, Shin YH, Kim JH, Lee JS, Jeong HJ (2005) Henoch-Schönlein purpura nephritis with nephrotic-range proteinuria: histological regression possibly associated with cyclosporin A and steroid treatment. Scand J Rheumatol 34:392–395PubMedCrossRefGoogle Scholar
  23. 23.
    Chartapisak W, Opastirakul S, Hodson EM, Willis NS, Craig JC (2009) Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP). Cochrane Database Syst Rev CD005128Google Scholar

Copyright information

© IPNA 2010

Authors and Affiliations

  • Jee Min Park
    • 1
  • Sung Chul Won
    • 2
  • Jae Il Shin
    • 2
  • Hyunee Yim
    • 3
  • Ki Soo Pai
    • 1
    Email author
  1. 1.Department of PediatricsAjou University School of MedicineSuwonKorea
  2. 2.Department of PediatricsYonsei University College of MedicineSeoulKorea
  3. 3.Department of PathologyAjou University School of MedicineSuwonKorea

Personalised recommendations